A Dose-Escalation Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP 1 and PARP 2 Inhibitor) in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma.

Trial Profile

A Dose-Escalation Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CEP-9722 (a PARP 1 and PARP 2 Inhibitor) in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors or Mantle Cell Lymphoma.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs CEP 9722 (Primary) ; Cisplatin; Gemcitabine
  • Indications Mantle-cell lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Cephalon
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Nov 2011 Official Title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top